Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 8/20 | 0.61 |
| ▸ | SI | P14410 | 6/20 | 0.61 |
| ▸ | GLB1 | P16278 | 2/20 | 0.57 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | TREH | O43280 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408655 | 1.00 | MGAM (0.61) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14416125 | 1.00 | MGAM (0.61) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14408591 | 0.83 | MGAM (0.65) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL10033385 | 0.83 | MGAM (0.65) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14408753 | 0.81 | MGAM (0.67) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14408748 | 0.78 | MGAM (0.54) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL13310709 | 0.78 | MGAM (0.54) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL10033383 | 0.78 | MGAM (0.54) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14416329 | 0.77 | MGAM (0.58) | MGAMSIGLB1GBA1TREH | |
| SCHEMBL14408740 | 0.76 | MGAM (0.56) | MGAMSIGLB1GBA1TREH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211945-B2 | Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient | SEIKAGAKU CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-7790773-B2 | Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient | SEIKAGAKU CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090281051-A1 | CARBA-SUGAR AMINE DERIVATIVE AND GLYCOLIPID METABOLIC DISORDER TREATING AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | SEIKAGAKU CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281051-A1 | CARBA-SUGAR AMINE DERIVATIVE AND GLYCOLIPID METABOLIC DISORDER TREATING AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MGLL, GPR119, GLA | MGAM 7/4885SI 278/4885GLB1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.